RxDoctor Payments Data

Jennifer Harper

Family · Fernandina Beach, FLNPI 1689111304

Payments from drug & device makers

$5,143in general payments, 2019–2025

Across 264 payments — averaging $19.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$705
  • Novo Nordisk$424
  • GSK$382
  • Lilly USA, LLC$379
  • Bayer$341
  • Abbott$219
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$5,143100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,143 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$75,427
Medicare patients
438
Services billed
2,122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide62$93,158
JardianceEmpagliflozin42$36,165
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$23,641
MounjaroTirzepatide20$21,388
EliquisApixaban21$20,804
Rosuvastatin Calcium139$2,110
Celecoxib60$2,078
SynthroidLevothyroxine Sodium16$1,864
Estradiol31$1,544
Levothyroxine Sodium139$1,265
Desvenlafaxine Succinate ErDesvenlafaxine Succinate13$1,241
Bupropion XlBupropion Hcl41$1,159
Atorvastatin Calcium107$1,048
Fluticasone Propionate56$825
Escitalopram Oxalate73$779

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$424$93,15862 claims
Boehringer IngelheimJardiance$194$36,16542 claims
GSKTrelegy Ellipta$382$23,64131 claims
Lilly USA, LLCMounjaro$379$21,38820 claims
PfizerEliquis$74$20,80421 claims
AbbVieSynthroid$705$1,86416 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$29$1,265139 claims
Almatica Pharma LLCSertraline Hcl$49$30631 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.

Other family in Fernandina Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →